CINNAMIC ACID HYDROXYAMIDES AS INHIBITORS OF HISTONE DEACETYLASE 8
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
1 . A compound having a structure of Formula I:
wherein:
R 1 and R 2 are each independently H, OH, halogen, or C 1 -C 6 alkyl;
L and L a are each independently a bond, O, S, NR 3 , —NR 10 C(═O)—R 11 , S(═O), S(═O) 2 , NHS(═O) 2 , —C 1 -C 6 alkylene-, —C 2 -C 6 alkenylene-, —C 2 -C 6 alkynylene-, —C 1 -C 6 heteroalkylene-, —C 1 -C 6 alkylene-O—, —C 1 -C 3 alkylene-O—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-NR 3 —, —C 1 -C 3 alkylene-NR 3 —C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-C(═O)NR 3 —, —C 1 -C 3 alkylene-C(═O)NR 3 —C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-NR 3 C(═O)—, —C 1 -C 3 alkylene-NR 3 C(═O)—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-S—, —C 1 -C 3 alkylene-S—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-S(═O)—, —C 1 -C 3 alkylene-S(═O)—C 1 -C 3 alkylene, —C 1 -C 6 alkylene-S(═O) 2 —, —C 1 -C 3 alkylene-S(═O) 2 —C 1 -C 3 alkylene, C(═O)—, or C(═O)—C 1 -C 6 alkylene;
X is a substituted or unsubstituted group selected from among aryl, heteroaryl, C 3 -C 10 cycloalkyl, and C 2 -C 10 heterocycloalkyl; where if X is substituted, then X is substituted with 1, 2, 3, 4, or 5 groups selected from among halogen, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, aminoC 1 -C 6 alkoxy, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, —CN, —NO 2 , —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 , —N(R 10 ) 2 , —C 1 -C 2 alkylN(R 10 ) 2 , C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
Y is H or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, —CO 2 R 10 , —C(═O)R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , aryl, heteroaryl, C 3 -C 10 cycloalkyl, and C 2 -C 10 heterocycloalkyl; where if Y is substituted, then Y is substituted with 1, 2, 3, 4, or 5 groups selected from among halogen, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, aminoC 1 -C 6 alkoxy, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, —CN, —NO 2 , —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 , —N(R 10 ) 2 , —C 1 -C 2 alkylN(R 10 ) 2 , C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;
R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;
R 3 is H, C 1 -C 6 alkyl, phenyl or benzyl;
or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug thereof.
2 . A compound having the structure of Formula (IV), Formula (IVa), Formula (IVb), or Formula (IVc):
wherein
L and L a are each independently a bond, O, S, NR 3 , —NR 10 C(═O)—R 11 , S(═O), S(═O) 2 , NHS(═O) 2 , —C 1 -C 6 alkylene-, —C 2 -C 6 alkenylene-, —C 2 -C 6 alkynylene-, —C 1 -C 6 heteroalkylene-, —C 1 -C 6 alkylene-O—, —C 1 -C 3 alkylene-O—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-NR 3 —, —C 1 -C 3 alkylene-NR 3 —C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-C(═O)NR 3 —, —C 1 -C 3 alkylene-C(═O)NR 3 —C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-NR 3 C(═O)—, —C 1 -C 3 alkylene-NR 3 C(═O)—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-S—, —C 1 -C 3 alkylene-S—C 1 -C 3 alkylene-, —C 1 -C 6 alkylene-S(═O)—, —C 1 -C 3 alkylene-S(═O)—C 1 -C 3 alkylene, —C 1 -C 6 alkylene-S(═O) 2 —, —C 1 -C 3 alkylene-S(═O) 2 —C 1 -C 3 alkylene, —C(═O)—, or —C(═O)—C 1 -C 6 alkylene;
X is a substituted or unsubstituted group selected from among aryl, heteroaryl, C 3 -C 10 cycloalkyl, and C 2 -C 10 heterocycloalkyl; where if X is substituted, then X is substituted with 1, 2, 3, 4, or 5 groups selected from among halogen, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, aminoC 1 -C 6 alkoxy, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, —CN, —NO 2 , —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 —R 11 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 1 , N(R 10 ) 2 , —C 1 -C 2 alkylN(R 10 ) 2 , C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
Y is H or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, —CO 2 R 10 , —C(═O)R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , aryl, heteroaryl, C 3 -C 10 cycloalkyl, and C 2 -C 10 heterocycloalkyl; where if Y is substituted, then Y is substituted with 1, 2, 3, 4, or 5 groups selected from among halogen, C 1 -C 6 alkoxy, C 1 -C 6 fluoroalkoxy, aminoC 1 -C 6 alkoxy, C 1 -C 3 alkylaminoC 1 -C 3 alkoxy, hydroxyC 1 -C 3 alkylaminoC 1 -C 3 alkoxy, C 2 -C 8 heterocyclo alkylC 1 -C 3 alkoxy, C 2 -C 8 heterocycloalkylC 1 -C 2 alkyl, —CN, —NO 2 , —CO 2 R 10 , —C(═O)R 11 , —S—R 11 , —S(═O)—R 11 , —S(═O) 2 —R 11 , —NR 10 C(═O)—R 11 , —C(═O)N(R 10 ) 2 , —S(═O) 2 N(R 10 ) 2 , —NR 10 S(═O) 2 , —OC(═O)N(R 10 ) 2 , —NR 10 C(═O)O—R 11 , —OC(═O)O—R 11 , —NHC(═O)NH—R 11 , —OC(═O)—R 11 , —N(R 10 ) 2 , —C 1 -C 2 alkylN(R 10 ) 2 . C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, substituted or unsubstituted C 2 -C 10 heterocycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
R 10 is hydrogen, or a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;
R 11 is a substituted or unsubstituted group selected from among C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 heterocycloalkyl, aryl, and heteroaryl;
R 3 is H, C 1 -C 6 alkyl, phenyl or benzyl;
R 1 and R 2 are each independently H; and n is an integer from 0 to 4.
3 . The compound of claim 1 wherein R 1 and R 2 are each independently H; and L is O or S.
4 . The compound of claim 1 wherein X is a substituted or unsubstituted phenyl.
5 . (canceled)
6 . The compound of claim 4 wherein
phenyl is substituted with at least one Cl, Br, I, or F; or
phenyl is substituted with at least two of Cl, Br, I, or F; or
phenyl is substituted with at least one C 1 -C 6 alkyl; or
phenyl is substituted with at least one C 1 -C 6 alkoxy.
7 .- 12 . (canceled)
13 . The compound of claim 1 wherein X is a substituted or unsubstituted heteroaryl.
14 . The compound of claim 13 wherein heteroaryl is pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, 4-azaindolyl, 5-azaindolyl, 6-azaindolyl, 7-azaindolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothienyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, imidazo[1,2-a]pyridinyl, thiophenopyridinyl, and furopyridinyl.
15 . The compound of claim 14 wherein heteroaryl is pyridinyl.
16 . The compound of claim 1 wherein X is a substituted or unsubstituted C 3 -C 10 cycloalkyl.
17 . (canceled)
18 . The compound of claim 1 wherein X is a substituted or unsubstituted C 2 -C 10 heterocycloalkyl.
19 . The compound of claim 18 wherein C 2 -C 10 heterocycloalkyl is quinolizinyl, dioxinyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazinyl, tetrahydropyridinyl, piperazinyl, oxazinanonyl, dihydropyrrolyl, dihydroimidazolyl, tetrahydrofuranyl, tetrahydropyranyl, dihydrooxazolyl, oxiranyl, pyrrolidinyl, pyrazolidinyl, dihydrothienyl, imidazolidinonyl, pyrrolidinonyl, dihydrofuranonyl, dioxolanonyl, thiazolidinyl, piperidinonyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and tetrahydrothienyl.
20 . The compound of claim 19 wherein C 2 -C 10 heterocycloalkyl is piperidinyl.
21 . The compound of claim 20 wherein piperidinyl is substituted with —CO 2 R 10 , —C(═O)R 11 or —C(═O)N(R 10 ) 2 .
22 .- 30 . (canceled)
31 . A compound selected from (E)-N-hydroxy-3-(2-(3-methoxyphenoxy)phenyl)acrylamide; (E)-3-(2-(3-fluorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-N-hydroxy-3-(2-(pyridin-3-yloxy)phenyl)acrylamide; (E)-N-hydroxy-3-(2-(pyridin-4-yloxy)phenyl)acrylamide; (E)-N-hydroxy-3-(2-(4-methoxyphenoxy)phenyl)acrylamide; (E)-3-(2-(3-chlorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3,4-dichlorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-N-hydroxy-3-(2-(m-tolyloxy)phenyl)acrylamide; (E)-N-hydroxy-3-(2-phenoxyphenyl)acrylamide; (E)-N-hydroxy-3-(2-(p-tolyloxy)phenyl)acrylamide; (E)-3-(2-(4-chlorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)phenyl)-N-hydroxyacrylamide; (S,E)-3-(2-(1-benzoylpiperidin-3-yloxy)phenyl)-N-hydroxyacrylamide; (S,E)-3-(2-(1-acetylpiperidin-3-yloxy)phenyl)-N-hydroxyacrylamide; (S,E)-N-hydroxy-3-(2-(1-isobutyrylpiperidin-3-yloxy)phenyl)acrylamide; (E)-3-(2-(1-(furan-2-carbonyl)piperidin-4-yloxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(1-acetylpiperidin-4-yloxy)phenyl)-N-hydroxyacrylamide; (E)-N-hydroxy-3-(2-(1-isobutyrylpiperidin-4-yloxy)phenyl)acrylamide; (E)-3-(2-(1-benzoylpiperidin-4-yloxy)phenyl)-N-hydroxyacrylamide; (E)-N-hydroxy-3-(2-(1-nicotinoylpiperidin-4-yloxy)phenyl)acrylamide; (R,E)-3-(2-(1-acetylpiperidin-3-yloxy)phenyl)-N-hydroxyacrylamide; (S,E)-3-(2-(1-(furan-2-carbonyl)piperidin-3-yloxy)phenyl)-N-hydroxyacrylamide; (R,E)-3-(2-(1-(furan-2-carbonyl)piperidin-3-yloxy)phenyl)-N-hydroxyacrylamide; (R,E)-N-hydroxy-3-(2-(1-isobutyrylpiperidin-3-yloxy)phenyl)acrylamide; (R,E)-3-(2-(1-benzoylpiperidin-3-yloxy)phenyl)-N-hydroxyacrylamide; (R,E)-N-hydroxy-3-(2-(1-nicotinoylpiperidin-3-yloxy)phenyl)acrylamide; (S,E)-N-hydroxy-3-(2-(1-nicotinoylpiperidin-3-yloxy)phenyl)acrylamide; (E)-N-(4-(4-fluorophenoxy)-3-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)nicotinamide; (E)-3-(5-acetamido-2-(4-fluorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(5-acetamido-2-(3-chlorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-N-(4-(3-chlorophenoxy)-3-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)nicotinamide; (E)-N-(4-(3-fluorophenoxy)-3-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)nicotinamide; (E)-N-(4-(3,4-dichlorophenoxy)-3-(3-(hydroxyamino)-3-oxoprop-1-enyl)phenyl)nicotinamide; (E)-3-(5-acetamido-2-(3-fluorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-5-(methylsulfonamido)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-5-(methylsulfonamido)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-5-(pyridin-2-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-5-(pyridin-2-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-fluorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3,4-dichlorophenoxy)-5-(pyridin-3-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-fluorophenoxy)-5-(pyridin-2-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3,4-dichlorophenoxy)-5-(pyridin-2-ylmethylamino)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-4-(pyridin-3-ylmethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-4-(2-morpholinoethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-4-(2-(dimethylamino)ethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-chlorophenoxy)-4-(2-methoxyethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-fluorophenoxy)-4-(2-methoxyethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(4-(2-acetamidoethoxy)-2-(3-chlorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-fluorophenoxy)-4-(2-(dimethylamino)ethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3-fluorophenoxy)-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-4-(2-methoxyethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-4-(pyridin-3-ylmethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-4-(2-(dimethylamino)ethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(4-(2-acetamidoethoxy)-2-(4-fluorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(4-fluorophenoxy)-4-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3,4-dichlorophenoxy)-4-(2-methoxyethoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(4-(2-acetamidoethoxy)-2-(3,4-dichlorophenoxy)phenyl)-N-hydroxyacrylamide; (E)-3-(2-(3,4-dichlorophenoxy)-4-(2-morpholinoethoxy)phenyl)-N-hydroxyacrylamide; and (E)-3-(2-(3,4-dichlorophenoxy)-4-(pyridin-3-ylmethoxy)phenyl)-N-hydroxyacrylamide; an active metabolite, pharmaceutically acceptable solvate, pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug thereof.
32 . A pharmaceutical composition comprising (a) a compound of claim 1 or an active metabolite, pharmaceutically acceptable solvate, pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, or pharmaceutically acceptable prodrug thereof, and (b) a pharmaceutically acceptable diluent, excipient, or carrier.
33 .- 34 . (canceled)
35 . A method of treating T-cell lymphoma or leukemia in a mammal in need thereof, comprising administering to the mammal a pharmaceutical composition containing a therapeutically effective amount of a compound of claim 1 .
36 . The method of claim 35 , further comprising administering to the mammal a second therapeutic agent, selected from among abarelix; aldesleukin; Aldesleukin; Alemtuzumab; alitretinoin; allopurinol; altretamine; amifostine; anastrozole; arsenic trioxide; asparaginase; azacitidine; bevacizumab; bexarotene; bleomycin; bortezomib; busulfan; busulfan; calusterone; capecitabine; carboplatin; carmustine; carmustine; celecoxib; cetuximab; chlorambucil; cisplatin; cladribine; clofarabine; cyclophosphamide; cytarabine; cytarabine liposomal; dacarbazine; dactinomycin; Darbepoetin alfa; dasatinib; daunorubicin liposomal; daunorubicin; daunorubicin; decitabine; denileukin; dexrazoxane; docetaxel; doxorubicin; doxorubicin liposomal; dromostanolone propionate; epirubicin; Epirubicin; Epoetin alfa; erlotinib; estramustine; etoposide phosphate; etoposide; exemestane; Filgrastim; floxuridine; fludarabine; fluorouracil; fulvestrant; gefitinib; gemcitabine; gemtuzumab ozogamicin; goserelin acetate; histrelin acetate; hydroxyurea; Ibritumomab Tiuxetan; idarubicin; ifosfamide; imatinib mesylate; interferon alfa 2a; Interferon alfa-2b; irinotecan; lenalidomide; letrozole; leucovorin; Leuprolide Acetate; levamisole; lomustine; meclorethamine, nitrogen mustard; megestrol acetate; melphalan; mercaptopurine; methotrexate; methoxsalen; mitomycin C; mitomycin C; mitotane; mitoxantrone; nandrolone phenpropionate; nelarabine; Nofetumomab; Oprelvekin; oxaliplatin; paclitaxel; paclitaxel; paclitaxel protein-bound particles; palifermin; pamidronate; panitumumab; pegademase; pegaspargase; Pegfilgrastim; pemetrexed disodium; pentostatin; pipobroman; plicamycin, mithramycin; porfimer sodium; procarbazine; quinacrine; Rasburicase; rituximab; sargramostim; Sargramostim; sorafenib; streptozocin; sunitinib maleate; tamoxifen; temozolomide; teniposide; testolactone; thalidomide; thioguanine; thiotepa; topotecan; toremifene; tositumomab; tositumomab/1-131 tositumomab; trastuzumab; tretinoin; Uracil Mustard; valrubicin; vinblastine; vincristine; vinorelbine; vorinostat; zoledronate; and zoledronic acid.
37 .- 38 . (canceled)
39 . A method of treating a disease or condition mediated by interleukin-1 beta (IL-1b) or IL-18 in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, pharmaceutically acceptable N-oxide, pharmaceutically active metabolite, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof.
40 . The method of claim 39 , wherein the disease or condition is selected from among osteoarthritis, rheumatoid arthritis, septic arthritis, gout, pseudogout, juvenile arthritis, Still's disease, Ankylosing spondylitis, systemic lupus erythematosus (SLE), Henoch-Schnlein purpura, psoriatic arthritis, reactive arthritis (Reiter's syndrome), hemochromatosis, hepatitis, Wegener's granulomatosis, Familial Mediterranean fever (FMF), HIDS (hyperimmunoglobulinemia D and periodic fever syndrome), TRAPS (TNF-alpha receptor associated periodic fever syndrome), inflammatory bowel disease, Crohn's Disease, ulcerative colitis, recurrent fever, anemia, leukocytosis, asthma, chronic obstructive pulmonary disease, and myalgia.
41 . The method of claim 40 , further comprising administering to the mammal a second therapeutic agent, selected from among tacrolimus, cyclosporin, rapamicin, methotrexate, cyclophosphamide, azathioprine, mercaptopurine, mycophenolate, or FTY720, prednisone, cortisone acetate, prednisolone, methylprednisolone, dexamethasone, betamethasone, triamcinolone, beclometasone, fludrocortisone acetate, deoxycorticosterone acetate, aldosterone, aspirin, salicylic acid, gentisic acid, choline magnesium salicylate, choline salicylate, choline magnesium salicylate, choline salicylate, magnesium salicylate, sodium salicylate, diflunisal, carprofen, fenoprofen, fenoprofen calcium, fluorobiprofen, ibuprofen, ketoprofen, nabutone, ketolorac, ketorolac tromethamine, naproxen, oxaprozin, diclofenac, etodolac, indomethacin, sulindac, tolmetin, meclofenamate, meclofenamate sodium, mefenamic acid, piroxicam, meloxicam, celecoxib, rofecoxib, valdecoxib, parecoxib, etoricoxib, lumiracoxib, CS-502, JTE-522, L-745,337 and NS398, leflunomide, gold thioglucose, gold thiomalate, aurofin, sulfasalazine, hydroxychloroquinine, minocycline, infliximab, etanercept, adalimumab, abatacept, anakinra, interferon-β, interferon-γ, interleukin-2, allergy vaccines, antihistamines, antileukotrienes, beta-agonists, theophylline, and anticholinergics.
42 .- 43 . (canceled)